

JAMA | Original Investigation

Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion

The DIETFITS Randomized Clinical Trial

Christopher D. Gardner, PhD; John F. Trepanowski, PhD; Liana C. Del Gobbo, PhD; Michelle E. Hauser, MD; Joseph Rigdon, PhD; John P. A. Ioannidis, MD, DSc; Manisha Desai, PhD; Abby C. King, PhD

IMPORTANCE Dietary modification remains key to successful weight loss. Yet, no one dietary strategy is consistently superior to others for the general population. Previous research suggests genotype or insulin-glucose dynamics may modify the effects of diets.

OBJECTIVE To determine the effect of a healthy low-fat (HLF) diet vs a healthy low-carbohydrate (HLC) diet on weight change and if genotype pattern or insulin secretion are related to the dietary effects on weight loss.

DESIGN, SETTING, AND PARTICIPANTS The Diet Intervention Examining The Factors Interacting with Treatment Success (DIETFITS) randomized clinical trial included 609 adults aged 18 to 50 years without diabetes with a body mass index between 28 and 40. The trial enrollment was from January 29, 2013, through April 14, 2015; the date of final follow-up was May 16, 2016. Participants were randomized to the 12-month HLF or HLC diet. The study also tested whether 3 single-nucleotide polymorphism multilocus genotype responsiveness patterns or insulin secretion (INS-30; blood concentration of insulin 30 minutes after a glucose challenge) were associated with weight loss.

INTERVENTIONS Health educators delivered the behavior modification intervention to HLF (n = 305) and HLC (n = 304) participants via 22 diet-specific small group sessions administered over 12 months. The sessions focused on ways to achieve the lowest fat or carbohydrate intake that could be maintained long-term and emphasized diet quality.

MAIN OUTCOMES AND MEASURES Primary outcome was 12-month weight change and determination of whether there were significant interactions among diet type and genotype pattern, diet and insulin secretion, and diet and weight loss.

RESULTS Among 609 participants randomized (mean age, 40 [SD, 7] years; 57% women; mean body mass index, 33 [SD, 3]; 244 [40%] had a low-fat genotype; 180 [30%] had a low-carbohydrate genotype; mean baseline INS-30, 93 μ IU/mL), 481 (79%) completed the trial. In the HLF vs HLC diets, respectively, the mean 12-month macronutrient distributions were 48% vs 30% for carbohydrates, 29% vs 45% for fat, and 21% vs 23% for protein. Weight change at 12 months was -5.3 kg for the HLF diet vs -6.0 kg for the HLC diet (mean between-group difference, 0.7 kg [95% CI, -0.2 to 1.6 kg]). There was no significant diet-genotype pattern interaction ($P = .20$) or diet-insulin secretion (INS-30) interaction ($P = .47$) with 12-month weight loss. There were 18 adverse events or serious adverse events that were evenly distributed across the 2 diet groups.

CONCLUSIONS AND RELEVANCE In this 12-month weight loss diet study, there was no significant difference in weight change between a healthy low-fat diet vs a healthy low-carbohydrate diet, and neither genotype pattern nor baseline insulin secretion was associated with the dietary effects on weight loss. In the context of these 2 common weight loss diet approaches, neither of the 2 hypothesized predisposing factors was helpful in identifying which diet was better for whom.

TRIAL REGISTRATION clinicaltrials.gov Identifier: [NCT01826591](https://clinicaltrials.gov/ct2/show/study/NCT01826591)

JAMA. 2018;319(7):667-679. doi:10.1001/jama.2018.0245

+ Supplemental content

+ CME Quiz at jamanetwork.com/learning and CME Questions page 715

Author Affiliations: Stanford Prevention Research Center, Department of Medicine, Stanford University Medical School, Stanford, California (Gardner, Trepanowski, Del Gobbo, Hauser, Ioannidis, King); Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California (Rigdon, Desai); Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California (Ioannidis, Desai, King); Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, California (Ioannidis, Desai); Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California (Ioannidis, Desai).

Corresponding Author: Christopher D. Gardner, PhD, Stanford Prevention Research Center, Department of Medicine, Stanford University Medical School, 1265 Welch Rd, Stanford, CA 94305 (cgardner@stanford.edu).

Obesity is a 21st-century major public health challenge.^{1,2} Among many strategies studied for weight loss, a common contrast has been low-fat diets vs low-carbohydrate diets.³⁻⁵ Most diet trials have reported modest (ie, <5%) mean weight loss after 12 months and negligible mean weight loss differences between diet groups.⁶ In contrast, individual weight losses have varied widely within diet groups in these studies, ranging from approximately 25 kg lost to approximately 5 kg gained.³⁻⁵

The substantial variability of weight loss response suggests some strategies may work better for some individuals than others, and that no one diet should be recommended universally.⁷ Yet, interindividual differences in response to diet are poorly understood. Some studies have reported that genotype variation could predispose individuals to differential weight loss that varies by diet type.^{8,9}

In a preliminary retrospective study, a 3-fold difference was observed in 12-month weight loss for initially overweight women who were determined to have been appropriately matched (mean weight loss of 6 kg) vs mismatched (mean weight loss of 2 kg) to a low-fat or low-carbohydrate diet based on multilocus genotype patterns with single-nucleotide polymorphisms (SNPs) from 3 genes (*PPARG*, *ADRB2*, and *FABP2*) relevant to fat and carbohydrate metabolism (a putative low-fat-responsive genotype and a low-carbohydrate-responsive genotype). The participants with the low-fat-responsive genotype were observed to lose more weight when assigned to a low-fat diet than those assigned to a low-carbohydrate diet, and vice versa for those with the low-carbohydrate-responsive genotype.^{9,10}

Similarly, several studies¹¹⁻¹⁴ have reported that baseline insulin dynamics may explain differential weight loss success obtained via a low-fat diet vs a low-carbohydrate diet. For example, individuals with greater insulin resistance may have better success with low-carbohydrate diets due to the decreased demand on insulin to clear a lower amount of dietary carbohydrate delivered to the circulation. However, these studies were limited by relatively small sample sizes or post hoc analyses of the results.

The primary objective of the Diet Intervention Examining The Factors Interacting with Treatment Success (DIETFITS) study was to test whether (1) a set of 3 SNP genotype patterns or (2) baseline differences in insulin secretion (the blood insulin concentration at 30 minutes after a glucose challenge; INS-30),^{12,13} or both, predisposed individuals to differential success in 12-month weight change while on a low-fat diet vs a low-carbohydrate diet.

Methods

The Stanford University human subjects committee approved the study. All study participants provided written informed consent.

Study Design

This single-site, parallel-group, weight loss diet trial randomized individuals to a healthy low-fat diet or a healthy

Key Points

Question What is the effect of a healthy low-fat (HLF) diet vs a healthy low-carbohydrate (HLC) diet on weight change at 12 months and are these effects related to genotype pattern or insulin secretion?

Findings In this randomized clinical trial among 609 overweight adults, weight change over 12 months was not significantly different for participants in the HLF diet group (-5.3 kg) vs the HLC diet group (-6.0 kg), and there was no significant diet-genotype interaction or diet-insulin interaction with 12-month weight loss.

Meaning There was no significant difference in 12-month weight loss between the HLF and HLC diets, and neither genotype pattern nor baseline insulin secretion was associated with the dietary effects on weight loss.

low-carbohydrate diet for 12 months. Participant enrollment began on January 29, 2013, and continued through April 14, 2015. The date of final follow-up was May 16, 2016. Interventions consisted primarily of class-based instruction. Five waves of recruitment (cohorts) had staggered start dates between March 2013 and March 2015. The primary outcome was 12-month weight change.

The first primary hypothesis was that there is a significant diet × genotype pattern interaction for weight loss. The second primary hypothesis was that there is a significant diet × insulin secretion interaction for weight loss. Secondary outcomes included anthropometric measures, plasma lipid levels, insulin and glucose levels, and blood pressure levels. The protocol update and statistical analysis plan are included in [Supplement 1](#) and the full study protocol was published previously¹⁰ (the protocol included details regarding blood sampling, storage, and specific laboratory assays).


Participants

We aimed to recruit 600 adults from the Stanford and San Francisco Bay areas of California using media advertisements and email lists from previous recruitment for nutrition studies conducted by our laboratory group. We considered men and premenopausal women aged 18 to 50 years with a body mass index (calculated as weight in kilograms divided by height in meters squared) of 28 to 40.

The major criteria for exclusion were having uncontrolled hypertension or metabolic disease; diabetes; cancer; heart, renal, or liver disease; and being pregnant or lactating. Individuals were excluded if taking hypoglycemic, lipid-lowering, antihypertensive, psychiatric, or other medications known to affect body weight or energy expenditure. Any medication type not noted was allowed if the individual had been stable while taking such medication for at least 3 months prior to baseline data collection.

Randomization to a healthy low-fat diet or a healthy low-carbohydrate diet was performed using an allocation sequence determined by computerized random-number

Figure 1. Flow of Participants Through the Diet Intervention Examining The Factors Interacting with Treatment Success Trial



^a Body mass index is calculated as weight in kilograms divided by height in meters squared.

^b To convert glucose to mmol/L, multiply by 0.0555.

generation (Blockrand in R version 3.4.0; R Project for Statistical Computing) in block sizes of 8 (with 4 individuals going to each diet) by a statistician not involved in intervention delivery or data collection. Participants did not learn of their diet group assignment until they completed all baseline measures and attended their first intervention class (Figure 1).

The original study design was a 2×2 factorial design (diet \times genotype-pattern matching). However, near the onset of the study, the initial funding was more than doubled, allowing for a 50% increase in sample size, the addition of a second primary hypothesis for the assessment of a diet \times insulin secretion interaction, and an expanded set of measurements. To test for both primary hypotheses, the study was changed to a simple parallel group design with testing for 2 interactions (described in further detail in eAppendix 1 in Supplement 2).

Weight Loss Intervention

The protocol included a 1-month run-in period during which participants were instructed to maintain their habitual diet, physical activity level, and body weight. The intervention involved 22 instructional sessions held over 12 months in diet-specific groups of approximately 17 participants per class. Sessions were held weekly for 8 weeks, then every 2 weeks for 2 months, then every 3 weeks until the sixth month, and monthly thereafter. Classes were led by 5 registered dietitian health educators who each taught 1 healthy low-fat class and 1 healthy low-carbohydrate class per cohort. Dietitians were blinded to all laboratory measures and genotype.

The dietary interventions were described previously.¹⁰ Briefly, the main goals were to achieve maximal differentiation in intake of fats and carbohydrates between the 2 diet groups while otherwise maintaining equal treatment

intensity and an emphasis on high-quality foods and beverages. Thus, participants were instructed to reduce intake of total fat or digestible carbohydrates to 20 g/d during the first 8 weeks. Higher priorities for reduction were given to specific foods and food groups that derived their energy content primarily from fats or carbohydrates. For example, the reduction of edible oils, fatty meats, whole-fat dairy, and nuts was prioritized for the healthy low-fat group, whereas the reduction of cereals, grains, rice, starchy vegetables, and legumes was prioritized for the healthy low-carbohydrate group.

Then individuals slowly added fats or carbohydrates back to their diets in increments of 5 to 15 g/d per week until they reached the lowest level of intake they believed could be maintained indefinitely. No explicit instructions for energy (kilocalories) restriction were given. Both diet groups were instructed to (1) maximize vegetable intake; (2) minimize intake of added sugars, refined flours, and *trans* fats; and (3) focus on whole foods that were minimally processed, nutrient dense, and prepared at home whenever possible. Other components of the emphasis on high-quality food for both diet groups are described elsewhere.¹⁰

Participants were encouraged to follow current physical activity recommendations.¹⁵ Health educators emphasized emotional awareness and behavior modification to support dietary adherence and weight loss. Behavioral modification strategies included empirically supported principles of self-regulatory behavior change (eg, goal setting, self-efficacy building, supportive environments, and relapse prevention) based on social cognitive theory and the transtheoretical model.^{10,16-18}

Outcome Measurements

All data were collected at baseline and at months 3, 6, and 12 for all cohorts unless noted otherwise. Staff who measured outcomes were blinded to diet assignment, genotype pattern, INS-30, and diet assignment. Dietary intake at each time point was assessed using 3 unannounced 24-hour multiple-pass recall interviews (2 on weekdays and 1 on a weekend day).¹⁹

Total energy expenditure was assessed using the Stanford Seven-Day Physical Activity Recall questionnaire.²⁰ Both the dietary intake and physical activity recall were self-reported measures. Weight was measured by digital scale at the Stanford Clinical Translational Research Unit and 12-month weight change was the primary outcome.

Genotype pattern and insulin secretion were assessed for interaction testing. The Affymetrix UK Biobank Axiom microarray was used for analysis of 820 967 SNPs and insertions or deletions. The array included 2 of the SNPs from the original study design: *PPARG* (rs1801282) and *ADRB2* (rs1042714). *FABP2* (rs1799883) was imputed with an imputation quality score ($r^2 = 0.99$). Additional details appear in eAppendix 2 in Supplement 2. The 3 SNP multilocus genotype patterns have been explored previously.⁹

Of 27 possible 3-locus genotypes that could arise from the combination of the 3 SNPs, 15 were observed with 1% or greater genotype frequency in previously studied samples of adults. The multilocus genotypes were grouped into those predicted to be more sensitive to fat (low-fat geno-

type; patterns 1-5), more sensitive to carbohydrates (low-carbohydrate genotype; patterns 6-14), or sensitive to neither genotype (pattern 15). Additional details are available in eAppendix 3 in Supplement 2.

Before randomization and at months 6 and 12, each participant completed an oral glucose tolerance test of 75 g. This included measurement of insulin concentration 30 minutes after glucose consumption (ie, INS-30, which is a proxy measure of insulin secretion).^{10,21,22} When this study was first designed, insulin sensitivity was to be measured and used as a predictor of differential weight loss success. After the study was initiated, reports were published^{12,13,23,24} indicating INS-30 was a successful predictor of weight loss in the context of low-carbohydrate diets or similar diets. There also was evidence²⁵ that early-phase insulin secretion differed markedly between diets that were similar to those tested in the DIETFITS study. Prior to examining any data, we modified the primary hypothesis of our study and tested baseline INS-30 rather than a measure of insulin sensitivity as the putative effect modifier. No other glucose or insulin variables were tested for effect modification.

A set of related secondary outcomes was assessed. Concentrations of plasma lipids, glucose, and insulin were measured in fasting samples, waist circumference was assessed by measuring tape, blood pressure was measured via automated device, and all of these were assessed using standard assessment techniques.¹⁰

Body composition was assessed by dual-energy x-ray absorptiometry and both respiratory exchange ratio (bounded by 0.7 [using solely fat for fuel] and 1.0 [using solely glucose for fuel]) and resting energy expenditure were assessed by metabolic cart (ie, measures respiratory exchange of oxygen and carbon dioxide while a participant is supine and resting) at baseline and at months 6 and 12 in cohorts 2 through 5. Adequate funding became available for dual-energy x-ray absorptiometry, respiratory exchange ratio, and resting energy expenditure only after cohort 1 was enrolled. The metabolic syndrome was determined using Adult Treatment Panel III guidelines from the National Cholesterol Education Program.²⁶

Statistical Analysis

Based on the original study design, assuming 100 participants in each of the 4 relevant groups (genotype and dietary assignment), and normally distributed values of weight change at 12 months, there was 80% power to detect clinically meaningful differences in treatment effect by genotype (eg, whether dietary assignment had an effect on weight change at 12 months except for those assigned to the low-carbohydrate diet who have the low-carbohydrate genotype because such individuals lose 3.2 kg on average). This calculation was based on simulations, and assumed a 2-sided Wald test conducted at the .05 level of significance.

Under similar assumptions regarding the statistical testing and type I error, and assuming a sample size of only 400 participants (200 in each treatment group), there was greater than 80% power to detect differences in the treatment effect with insulin secretion, including for example,

if for every 1-unit increase in insulin secretion, weight loss at 12 months increases by 0.8 lb (0.36 kg). These power calculations were performed a priori for the originally planned sample size of 400. As described in greater detail in eAppendix 1 in Supplement 2, after initially being funded by the National Institutes of Health and the National Institute of Diabetes and Digestive and Kidney Diseases in 2012, additional funding was received to augment the trial, which involved, among other modifications, increasing the sample size from 400 to 600, and adding INS-30 as a second variable for interaction testing. With the larger sample size, the study had even greater statistical power, estimated at 90% based on post hoc calculations.

The main hypotheses addressed 12-month weight change by diet, diet and genotype, and diet and baseline INS-30. All hypotheses were addressed using generalized, linear mixed-effects models.^{27,28} We applied modified intent-to-treat principles. This means that all participants who were randomized and had baseline information were included in the analysis and analyzed according to original treatment assignment, regardless of adherence or loss to follow-up (Figure 1). For the hypothesis about the effect of diet group on 12-month weight change, a linear mixed-effects model for weight that accounted for missing data under flexible assumptions regarding missingness was used with fixed effects for diet, time (baseline, 3, 6, and 12 months), and their interaction, along with a random effect for participant. For the hypotheses involving diet and genotype (or diet and baseline INS-30), an additional fixed effect was added for genotype (or baseline INS-30), along with all 2- and 3-way interactions (model appears in eAppendix 4 in Supplement 2).

The validity of such an analysis relies on the assumption that the missing outcome data measured at follow-up are unrelated to unobserved values of weight conditional on observed variables such as treatment assignment and baseline and intermittent values of weight. The hypothesis about diet was tested using a Wald test for the 2-way interaction between the 12-month time point and diet. The hypothesis about genotype (or baseline INS-30) was tested using a Wald test for the 3-way interaction between the 12-month time point, diet, and genotype (or baseline INS-30). Genotype was defined as matched for those participants with a 3-SNP combination suggesting success on a low-carbohydrate diet who were randomized to the low-carbohydrate diet, or for those participants with a 3-SNP combination suggesting success on a low-fat diet who were randomized to the low-fat diet. Genotype was otherwise defined as mismatched and is described in eAppendices 2 and 3 in Supplement 2.

There were 185 individuals who were not classified as having either the low-fat genotype pattern or a low-carbohydrate genotype pattern (146 individuals with other 3-SNP patterns and 39 with missing or compromised genotyping data) who were excluded from the genotype analysis for the first hypothesis as originally planned.¹⁰ An additional diet-genotype analysis was performed, restricting the study population to whites only and focusing on only 1 ancestry group as originally planned.¹⁰ The second hypothesis was tested using a Wald test for the interaction among diet, 12-month

time point, and baseline INS-30. The INS-30 variable was analyzed as a continuous variable, but is presented as tertiles for ease of presentation in parallel to the presentation of genotype pattern data. The cutoffs for the tertiles were determined using the baseline insulin concentrations of all 609 participants.

A Satterthwaite approximation for denominator degrees of freedom was used in all Wald tests.²⁹ All tests were 2-sided and conducted at the .05 level of significance. Formal hypothesis testing was performed only for the 2 primary hypotheses. All other *P* values that were generated were purely descriptive in nature and correspond to secondary and exploratory analyses. Statistical analyses were performed using R version 3.4.0 (R Project for Statistical Computing). Specifically, the lme4³⁰ package was used for mixed-effects models and the lmerTest²⁹ package was used for hypothesis tests in the mixed-effects models.

Results

Among 609 participants randomized (mean age, 40 [SD, 7] years; 57% women; mean body mass index, 33 [SD, 3]; 244 [40%] had a low-fat genotype; 180 [30%] had a low-carbohydrate genotype; mean baseline INS-30, 93 μ IU/mL), 481 (79%) completed the trial. The flow of the participants through the trial appears in Figure 1. Baseline characteristics by diet group appear in Table 1. Among participants in the healthy low-fat diet group, 130 (42.6%) had the low-fat genotype and 83 (27.2%) had the low-carbohydrate genotype, whereas in the healthy low-carbohydrate group, 114 (37.5%) had the low-fat genotype and 97 (31.9%) had the low-carbohydrate genotype.

Of 22 assigned intervention instruction sessions for the full study sample, the mean number of sessions attended was 14.4 (SD, 5.3) for the healthy low-fat diet group and 14.6 (SD, 5.1) for the healthy low-carbohydrate diet group, which includes dropouts. Retention at 12 months, which was defined as participants who provided any data at 12 months, was 79% for both groups. Participant ratings for health educator enthusiasm and knowledge of material was high and similar between diet groups. The mean ratings were 4.6 to 5.0 on a scale of 1 to 5, with 5 as the highest rating.

Total energy intake was not different between diet groups at baseline or at any subsequent time point ($P \geq .10$ for all; Table 2). Despite not being instructed to follow a specific energy (kilocalorie) intake restriction, the mean reported energy intake reduction relative to baseline was approximately 500 to 600 kcal/d for both groups at each time point after randomization.

At baseline, there were no significant between-group differences for any nutrients examined. In contrast, there were significant between-group differences after randomization at every time point (all $P \leq .001$) for percentage of energy; intakes of carbohydrates, fat, protein, saturated fat, fiber, and added sugars; and glycemic index and glycemic load (Table 2). In the healthy low-fat diet vs the healthy low-carbohydrate diet, respectively, the mean 12-month

Table 1. Baseline Demographics and Anthropometric and Metabolic Variables

	Healthy Low-Fat Diet (n = 305)	Healthy Low-Carbohydrate Diet (n = 304)
Sex, No. (%)		
Women	167 (54.8)	179 (58.9)
Men	138 (45.2)	125 (41.1)
Age, mean (SD), y	39.3 (6.8)	40.2 (6.7)
Highest level of education achieved, No. (%) ^a		
<High school degree	2 (0.6)	2 (0.6)
High school degree	5 (1.6)	11 (3.6)
Some college	63 (20.7)	67 (22.0)
College degree	102 (33.4)	106 (34.9)
Some postgraduate school	25 (8.2)	12 (3.9)
Postgraduate degree	107 (35.1)	103 (33.9)
Race/ethnicity, No. (%) ^b		
White	176 (57.7)	182 (59.9)
Hispanic	67 (22.0)	61 (20.1)
Asian	30 (9.8)	30 (9.9)
African American	10 (3.3)	13 (4.3)
American Indian, Alaskan Native, or Pacific Islander	3 (1.0)	0
Other	19 (6.2)	18 (5.9)
Weight, mean (SD), kg		
Women	90.7 (11.5)	88.9 (12.5)
Men	105.7 (13.9)	106.8 (13.7)
Both sexes	97.5 (14.7)	96.3 (15.7)
Body mass index, mean (SD) ^c		
Women	33.3 (3.4)	32.9 (3.4)
Men	33.5 (3.4)	33.8 (3.4)
Both sexes	33.4 (3.4)	33.3 (3.4)
Body fat %, mean (SD) ^d		
Women	41.0 (3.9)	40.4 (4.0)
Men	29.9 (4.5)	30.3 (4.7)
Both sexes	36.3 (6.9)	36.5 (6.6)
Waist circumference, mean (SD), cm ^e		
Women	103.5 (10.4)	102.6 (10.5)
Men	111.8 (9.7)	112.7 (9.9)
Both sexes	107.2 (10.9)	106.7 (11.4)
Blood lipid level, mean (SD), mmol/L		
High-density lipoprotein cholesterol	1.28 (0.23)	1.29 (0.24)
Low-density lipoprotein cholesterol ^f	2.89 (0.79)	2.94 (0.68)
Triglycerides	1.45 (0.80)	1.45 (1.03)
Blood pressure, mean (SD), mm Hg ^g		
Systolic	122.9 (12.5)	122.9 (12.4)
Diastolic	81.0 (7.3)	81.2 (7.8)
Fasting glucose, mean (SD), mg/dL	98.6 (8.6)	98.5 (9.7)
Fasting insulin, mean (SD), μIU/mL	15.9 (13.5)	15.5 (8.0)
Insulin-30, mean (SD), μIU/mL ^h	95.1 (67.5)	91.8 (61.7)
Metabolic syndrome, No. (%) ⁱ	106 (34.8)	100 (32.9)
Respiratory exchange ratio, mean (SD) ^{j,k}	0.861 (0.065)	0.862 (0.058)
Resting energy expenditure, mean (SD), kcal ^{l,k}	1651 (283)	1629 (293)
Energy expenditure, mean (SD), kcal/kg/d ^l	32.6 (1.7)	32.5 (2.2)
Genotype, No. (%) ^m		
Low fat	130 (42.6)	114 (37.5)
Low carbohydrate	83 (27.2)	97 (31.9)
Neither	70 (23.0)	76 (25.0)

SI conversion factors: To convert glucose to mmol/L, multiply by 0.0555; high-density and low-density lipoprotein cholesterol to mg/dL, divide by 0.0259; insulin to pmol/L, multiply by 6.945; triglycerides to mg/dL, divide by 0.0113.

^a There were missing data for 1 participant in the low-fat group and 3 participants in the low-carbohydrate group.

^b Determined by self-report using fixed categories.

^c Calculated as weight in kilograms divided by height in meters squared.

^d Available only for cohorts 2 through 5 because additional funding became available for use of dual-energy x-ray absorptiometry and technician time. There were missing data for 77 participants in the low-fat group and 66 participants in the low-carbohydrate group. In addition, 37 participants in the low-fat group and 28 participants in the low-carbohydrate group declined being measured.

^e There were missing data for 3 participants in the low-fat group and 2 participants in the low-carbohydrate group.

^f There were missing data for 1 participant in the low-carbohydrate group.

^g There were missing data for 2 participants in the low-fat group and 1 participant in the low-carbohydrate group.

^h Indicates the blood concentration of insulin at the 30-minute time point of an oral glucose tolerance test. There were missing data for 3 participants in the low-fat group.

ⁱ Defined by Adult Treatment Panel III guidelines from the National Cholesterol Education Program.²⁶

^j Available only for cohorts 2 through 5 because additional funding became available for metabolic cart and technician time.

^k There were missing data for 41 participants in the low-fat group and 40 participants in the low-carbohydrate group.

^l There were missing data for 23 participants in the low-fat group and 33 participants in the low-carbohydrate group.

^m There were missing data for 22 participants in the low-fat group and 17 participants in the low-carbohydrate group.

Table 2. Dietary Intake by Time Point

	Healthy Low-Fat Diet		Healthy Low-Carbohydrate Diet		Mean Between-Group Difference (95% CI) ^a
	No. of Participants	Mean (SD)	No. of Participants	Mean (SD)	
Total Energy Intake, kcal					
Baseline	304	2148.1 (39.4)	304	2222.8 (37.5)	-76.3 (-166.1 to 13.4)
3 mo	274	1515.0 (27.7)	275	1580.8 (29.1)	-56.9 (-150.2 to 36.4)
6 mo	240	1624.4 (37.3)	251	1621.3 (33.2)	0.2 (-96.9 to 97.3)
12 mo	225	1716.1 (34.5)	224	1697.1 (32.1)	2.9 (-97.2 to 103.0)
Carbohydrates, g					
Baseline	304	241.8 (5.0)	304	246.5 (4.5)	-4.9 (-16.6 to 6.9)
3 mo	274	205.2 (4.3)	275	96.6 (3.4)	109.0 (96.8 to 121.2)
6 mo	240	211.2 (5.3)	251	113.2 (4.1)	95.6 (83.0 to 108.3)
12 mo	225	212.9 (5.0)	224	132.4 (4.2)	74.2 (61.2 to 87.2)
Carbohydrates, % kcal					
Baseline	304	44.5 (0.5)	304	44.0 (0.4)	0.5 (-1.1 to 2.1)
3 mo	274	52.6 (0.6)	275	23.1 (0.7)	29.4 (27.8 to 31.0)
6 mo	240	50.8 (0.7)	251	26.5 (0.7)	24.1 (22.4 to 25.8)
12 mo	225	48.4 (0.7)	224	29.8 (0.7)	17.8 (16.0 to 19.5)
Fat, g					
Baseline	304	87.0 (2.0)	304	92.6 (1.9)	-5.6 (-10.4 to -0.8)
3 mo	274	42.0 (1.2)	275	88.8 (2.0)	-46.2 (-51.2 to -41.2)
6 mo	240	50.3 (1.8)	251	86.6 (2.0)	-36.0 (-41.2 to -30.8)
12 mo	225	57.3 (1.7)	224	86.2 (2.0)	-28.4 (-33.8 to -23.0)
Fat, % kcal					
Baseline	304	34.8 (0.4)	304	36.0 (0.3)	-1.2 (-2.4 to 0.1)
3 mo	274	24.0 (0.5)	275	49.0 (0.5)	-24.9 (-26.2 to -23.6)
6 mo	240	26.4 (0.6)	251	46.8 (0.6)	-20.3 (-21.7 to -18.9)
12 mo	225	28.7 (0.5)	224	44.6 (0.6)	-15.4 (-16.8 to -14.0)
Protein, g					
Baseline	304	92.1 (1.7)	304	93.1 (1.6)	-1.1 (-5.8 to 3.6)
3 mo	274	79.5 (1.6)	275	96.9 (2.0)	-17.1 (-22.0 to -12.2)
6 mo	240	81.9 (1.9)	251	93.8 (1.9)	-11.6 (-16.6 to -6.5)
12 mo	225	84.5 (1.8)	224	93.3 (2.0)	-8.5 (-13.8 to -3.3)
Protein, % kcal					
Baseline	304	17.9 (0.3)	304	17.3 (0.2)	0.6 (-0.4 to 1.5)
3 mo	274	21.5 (0.4)	275	25.9 (0.4)	-4.4 (-5.4 to -3.5)
6 mo	240	20.8 (0.4)	251	24.3 (0.4)	-3.5 (-4.5 to -2.5)
12 mo	225	20.6 (0.4)	224	22.9 (0.4)	-2.1 (-3.2 to -1.1)
Saturated Fat, g					
Baseline	304	28.9 (0.7)	304	30.8 (0.7)	-1.9 (-3.7 to -0.1)
3 mo	274	12.7 (0.4)	275	29.1 (0.7)	-16.2 (-18.1 to -14.3)
6 mo	240	15.3 (0.7)	251	27.9 (0.7)	-12.4 (-14.4 to -10.5)
12 mo	225	18.2 (0.6)	224	28.2 (0.8)	-9.8 (-11.8 to -7.8)
Saturated Fat, % kcal					
Baseline	304	11.5 (0.2)	304	11.9 (0.2)	-0.4 (-0.9 to 0.2)
3 mo	274	7.2 (0.2)	275	16.1 (0.3)	-8.8 (-9.4 to -8.2)
6 mo	240	8.0 (0.2)	251	15.0 (0.3)	-7.0 (-7.6 to -6.4)
12 mo	225	9.0 (0.2)	224	14.5 (0.3)	-5.3 (-5.9 to -4.7)
Fiber, g					
Baseline	304	22.0 (0.6)	304	21.6 (0.5)	0.4 (-1.2 to 1.9)
3 mo	274	24.2 (0.7)	275	16.7 (0.8)	7.5 (5.9 to 9.1)
6 mo	240	23.7 (0.7)	251	17.2 (0.5)	6.5 (4.8 to 8.2)
12 mo	225	23.0 (0.6)	224	18.6 (0.5)	4.1 (2.3 to 5.8)

(continued)

Table 2. Dietary Intake by Time Point (continued)

	Healthy Low-Fat Diet		Healthy Low-Carbohydrate Diet		Mean Between-Group Difference (95% CI) ^a
	No. of Participants	Mean (SD)	No. of Participants	Mean (SD)	
Fiber, g/1000 kcal					
Baseline	304	10.8 (0.2)	304	10.3 (0.2)	0.4 (-0.5 to 1.4)
3 mo	274	16.5 (0.4)	275	11.3 (0.6)	5.3 (4.3 to 6.3)
6 mo	240	15.4 (0.4)	251	11.2 (0.3)	4.2 (3.1 to 5.2)
12 mo	225	14.2 (0.4)	224	11.6 (0.3)	2.5 (1.4 to 3.5)
Added Sugars, g					
Baseline	304	49.3 (2.0)	304	52.2 (2.0)	-3.0 (-7.3 to 1.3)
3 mo	274	28.5 (1.3)	275	16.2 (1.2)	12.4 (8.0 to 16.9)
6 mo	240	31.5 (1.7)	251	18.9 (1.3)	12.2 (7.5 to 16.9)
12 mo	225	33.1 (1.7)	224	22.8 (1.6)	9.6 (4.7 to 14.5)
Sugar, g/1000 kcal					
Baseline	304	22.4 (0.7)	304	23.2 (0.7)	-0.8 (-2.7 to 1.1)
3 mo	274	18.4 (0.7)	275	9.8 (0.6)	8.6 (6.6 to 10.6)
6 mo	240	18.9 (0.8)	251	11.2 (0.7)	7.6 (5.5 to 9.7)
12 mo	225	18.7 (0.9)	224	12.9 (0.8)	5.6 (3.5 to 7.8)
Glycemic Index^b					
Baseline	304	57.8 (0.3)	304	58.2 (0.3)	-0.4 (-1.4 to 0.6)
3 mo	274	56.0 (0.3)	275	50.1 (0.4)	5.9 (4.9 to 7.0)
6 mo	240	56.2 (0.4)	251	51.4 (0.5)	4.7 (3.6 to 5.8)
12 mo	225	56.1 (0.4)	224	52.7 (0.5)	3.1 (2.0 to 4.3)
Glycemic Load^c					
Baseline	304	128.2 (2.9)	304	132.4 (2.7)	-4.3 (-11.1 to 2.6)
3 mo	274	102.1 (2.3)	275	43.1 (2.0)	59.0 (51.9 to 66.2)
6 mo	240	107.0 (3.1)	251	52.4 (2.5)	53.0 (45.6 to 60.4)
12 mo	225	108.0 (2.8)	224	62.9 (2.6)	41.5 (33.8 to 49.1)

^a Healthy low-fat diet minus healthy low-carbohydrate diet from linear mixed-effects model.

^b Indicates ranking of foods according to the potential of 50 g of carbohydrates from that food to raise blood glucose relative to 50 g of glucose (scale of 0-100; a score of 100 refers to the same rate as glucose).

^c Indicates the actual amount of carbohydrates multiplied by the glycemic index.

macronutrient distributions were 48% vs 30% for carbohydrates, 29% vs 45% for fat, and 21% vs 23% for protein.

Primary Outcome

The mean 12-month weight change was -5.3 kg (95% CI, -5.9 kg to -4.7 kg) for the healthy low-fat diet group and -6.0 kg (95% CI, -6.6 kg to -5.4 kg) for the healthy low-carbohydrate diet group, which was not statistically different (Table 3). There was a similar range for weight change of approximately 40 kg within each group (-30 kg to 10 kg; eFigure 1 in Supplement 2).

Interaction Testing

The test for the interaction among diet, genotype pattern, and the 12-month time point was not statistically significant. The interpretation of the beta coefficient for the 3-way interaction (beta coefficient, 1.38 [95% CI, -0.72 to 3.49], $P = .20$) is that 12-month weight change increases (estimated as 1.38 kg) when switching from a healthy low-carbohydrate diet and a low-carbohydrate genotype to a healthy low-fat diet and low-fat genotype beyond the main effects of switching from a healthy low-carbohydrate diet to a healthy low-fat diet and from a low-carbohydrate geno-

type to a low-fat genotype (Figure 2A). This indicates that there was no significant difference in weight change among participants matched vs mismatched to their diet assignment based on their 3-SNP genotype pattern. In analyses restricted to participants of European descent only, no significant interaction was observed by genotype pattern (the 3-way interaction for the main diet, genotype, and time yielded a beta coefficient of 2.58 [95% CI, -0.18 to 5.34]; $P = .07$).

Similarly, the test for interaction among diet, baseline insulin secretion (INS-30), and the 12-month time point was not statistically significant. The interpretation of the beta coefficient for the 3-way interaction (beta coefficient, 0.08 [95% CI, -0.13 to 0.28], $P = .47$) is that 12-month weight change increases (estimated as 0.08 kg) when switching from a healthy low-carbohydrate diet and x units of baseline INS-30 to a healthy low-fat diet and $x + 10$ units of baseline INS-30 beyond the effects of changing from a healthy low-carbohydrate diet to a healthy low-fat diet and increasing baseline INS-30 by 10 $\mu\text{IU/mL}$ (Figure 2B). Weight change trajectories for the diet-genotype pattern subgroups are presented in eFigure 2A and for diet and INS-30 tertile subgroups in eFigure 2B in Supplement 2.

Table 3. 12-Month Change Estimates for Anthropometric Variables by Diet

	12-mo Change Estimate (95% CI) ^a		
	Healthy Low-Fat Diet (n = 305)	Healthy Low-Carbohydrate Diet (n = 304)	Between-Group Difference (95% CI) ^b
Weight, kg	-5.29 (-5.93 to -4.65)	-5.99 (-6.63 to -5.35)	0.70 (-0.21 to 1.60)
Body mass index ^c	-1.75 (-1.97 to -1.52)	-2.07 (-2.30 to -1.85)	0.33 (0.01 to 0.64)
Body fat % ^d	-1.97 (-2.38 to -1.56)	-2.15 (-2.54 to -1.75)	0.18 (-0.40 to 0.75)
Waist circumference, cm	-3.74 (-4.64 to -2.84)	-4.41 (-5.31 to -3.51)	0.67 (-0.60 to 1.94)
Lipid level, mmol/L			
High-density lipoprotein cholesterol	0.40 (-0.37 to 1.18)	2.64 (1.87 to 3.41)	-2.24 (-3.33 to -1.15)
Low-density lipoprotein cholesterol	-2.12 (-4.70 to 0.47)	3.62 (1.04 to 6.19)	-5.74 (-9.38 to -2.09)
Triglycerides	-9.95 (-17.46 to -2.44)	-28.20 (-35.67 to -20.72)	18.25 (7.65 to 28.84)
Blood pressure, mm Hg			
Systolic	-3.18 (-4.33 to -2.03)	-3.72 (-4.86 to -2.58)	0.54 (-1.07 to 2.16)
Diastolic	-1.94 (-2.65 to -1.22)	-2.64 (-3.34 to -1.93)	0.70 (-0.31 to 1.71)
Fasting glucose, mg/dL	-3.67 (-4.90 to -2.44)	-2.10 (-3.32 to -0.87)	-1.58 (-3.31 to 0.16)
Fasting insulin, μ U/mL	-2.64 (-3.79 to -1.49)	-2.33 (-3.48 to -1.19)	-0.31 (-1.93 to 1.31)
Insulin-30, μ U/mL ^e	-15.38 (-21.13 to -9.62)	-11.48 (-17.18 to -5.78)	-3.90 (-12.00 to 4.20)
Metabolic syndrome, No. (%) ^f			
Had metabolic syndrome at baseline but not at 12 mo	36 (11.8)	36 (11.8)	
Had metabolic syndrome at baseline and 12 mo	39 (12.8)	36 (11.8)	
Did not have metabolic syndrome at baseline or 12 mo	128 (42.0)	137 (45.1)	
Did not have metabolic syndrome at baseline but had metabolic syndrome at 12 mo	13 (4.3)	11 (3.6)	
Respiratory exchange ratio ^g	-0.008 (-0.018 to 0.002)	-0.027 (-0.037 to -0.018)	0.020 (0.006 to 0.033)
Resting energy expenditure, kcal ^g	-66.45 (-96.65 to -36.26)	-76.93 (-106.68 to -47.19)	10.48 (-31.91 to 52.87)
Energy expenditure, kcal/kg/d	0.55 (0.20 to 0.90)	0.49 (0.13 to 0.84)	0.06 (-0.44 to 0.56)

SI conversion factors: To convert glucose to mmol/L, multiply by 0.0555; high-density and low-density lipoprotein cholesterol to mg/dL, divide by 0.0259; insulin to pmol/L, multiply by 6.945; triglycerides to mg/dL, divide by 0.0113.

^a Data were missing for 91 participants in the healthy low-fat diet group and 86 in the healthy low-carbohydrate diet group (almost exclusively due to dropout).

^b Healthy low-fat diet minus healthy low-carbohydrate diet.

^c Calculated as weight in kilograms divided by height in meters squared.

^d There were missing data for 138 participants in the healthy low-fat diet group

and 123 in the healthy low-carbohydrate diet group. This was due to a combination of dropout and not having any data for cohort 1.

^e Indicates the blood concentration of insulin at the 30-minute time point of an oral glucose tolerance test.

^f Defined by Adult Treatment Panel III guidelines from the National Cholesterol Education Program.²⁶

^g There were missing data for 125 participants in the healthy low-fat diet group and 121 in the healthy low-carbohydrate diet group due to a combination of dropout and not having any data for cohort 1.

Secondary Outcomes


There were improvements in the secondary outcomes for both diet groups. However, there were no significant between-group differences observed for body mass index, body fat percentage, and waist circumference (Table 3). At 12 months relative to baseline, both diets improved lipid profiles and lowered blood pressure, insulin, and glucose levels, with the exception of low-density lipoprotein cholesterol concentrations, which increased for participants in the healthy low-carbohydrate group (Table 3). The 12-month changes in low-density lipoprotein cholesterol concentrations significantly favored a healthy low-fat diet. High-density lipoprotein cholesterol concentrations increased significantly more and concentrations of triglycerides decreased significantly more for the healthy low-carbohydrate diet group than for the healthy low-fat diet group. The decrease in the prevalence of the metabolic syndrome was not significantly different between the diet groups.

Respiratory exchange ratio was not significantly different between the groups at baseline, but was lower for the healthy low-carbohydrate diet group than for the healthy low-fat diet group at each time point after randomization ($P < .001$; eTable 1 in Supplement 2). Resting energy expenditure was not significantly different between groups at baseline or at 6 months or 12 months, but decreased significantly from baseline in both diet groups. Total energy expenditure was not significantly different between groups at baseline or any other time point. Relative to baseline, there was a small absolute mean increase in energy expenditure for both diet groups that was not significantly different than baseline.

Adverse Events

During the trial, there were 7 serious adverse events, all requiring hospitalization; 2 of these could have been related to the study (kidney stones and diverticulitis requiring

Figure 2. Interaction Among Diet and Genotype and Diet and Insulin-30 Tertile at Baseline and 12-Month Weight Loss



The black solid circle indicates the mean, the left and right borders of the box mark the first and third quartiles, the black vertical line indicates the median, the error bars indicate the 5th and 95th percentiles, and the hollow circles indicate the individuals whose values were outside the 5th or 95th percentiles. The No. of participants reflect data for the individuals who had weight data at both baseline and 12 months. Statistical analyses include data from all individuals randomized (described in the Statistical Analysis section).

A, Three-way interaction term among diet, genotype, and the 12-month time point was not statistically significant (beta coefficient, 1.38 [95% CI, -0.72 to 3.49]; $P = .20$). As described in Stanton et al,¹⁰ of all the possible combinations of variance in 3 single-nucleotide polymorphism multilocus genotype patterns, some were considered consistent with the low-fat genotype pattern, some with the low-carbohydrate genotype pattern, and some with neither of

these 2 genotype patterns. By design, as described in the initial National Institutes of Health grant application, those individuals with neither of the main 2 genotype patterns were not included in the main analyses. There were 39 participants who had compromised or missing DNA.

B, Three-way interaction term among diet, insulin, and the 12-month time point was not statistically significant (beta coefficient for 10- μ U/mL increase in insulin, 0.08 [95% CI, -0.13 to 0.28]; $P = .47$). Insulin-30 is the blood concentration of insulin 30 minutes after consuming 75 g of glucose as part of a standard oral glucose tolerance test. Insulin-30 was treated as a continuous variable in the statistical model. Tertiles were used in this Figure for ease of presentation. The mean for the lowest tertile was 40.8 μ U/mL (range, 7.3-60.6 μ U/mL); middle, 80.1 μ U/mL (range, 60.7-103.1 μ U/mL); and highest, 159.6 μ U/mL (range, 103.4-562.5 μ U/mL).

surgery). There were 11 adverse events; 9 of these were related to the study or possibly related (eg, hypoglycemia following oral glucose tolerance test). Combined serious adverse events and adverse events were evenly distributed across the 2 diet groups.

Discussion

In this clinical trial of 609 generally healthy overweight or obese adults without diabetes who were randomly assigned to a healthy low-fat vs a healthy low-carbohydrate diet,

there was no significant difference in weight loss at 12 months. In addition, there were no significant interactions between diet and 3 SNP multilocus genotype patterns or diet and baseline insulin secretion on 12-month weight loss. These results were observed in the context of similar mean 12-month weight loss in both diet groups that was greater than 5% of baseline body weight, and a similar and substantial range of weight change, reflecting approximately 40 kg within each diet group (from losing approximately 30 kg to gaining approximately 10 kg).

Dietary intake of fats and carbohydrates was well differentiated between the 2 diet groups, as confirmed by diet

assessment, and corroborated by changes in blood lipid parameters and respiratory exchange ratio, indicating strong treatment fidelity. With the large sample size, good retention, substantial weight loss and weight loss variability, and good adherence to and differentiation of diets, the study was well positioned to detect significant interactions by the primary variables of interest if they existed. However, no such effects were observed. Differences in weight loss between the 2 groups were nonsignificant and not clinically meaningful.

Among the secondary outcomes, the clinical variables that were significantly different between the diet groups were the blood lipid results, which were more favorable in the healthy low-fat diet group for changes in low-density lipoprotein cholesterol and were more favorable in the healthy low-carbohydrate diet group for changes in high-density lipoprotein cholesterol and triglycerides. The magnitude of the between-group differences were 5% for low-density lipoprotein cholesterol, 5% for high-density lipoprotein cholesterol, and 15% for triglycerides.

There is considerable scientific interest in identifying genetic variants that help explain interindividual differences in weight loss success in response to diet interventions,^{31,32} particularly diets with varying macronutrient compositions. Multiple secondary analyses of low-fat and low-carbohydrate weight loss diet trials, including the Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) and the Nutrient-Gene Interactions in Human Obesity (NUGENOB) trials,^{8,32-34} have reported effect modification by SNPs on associations of dietary fat and carbohydrates with weight loss.

For example, Qi et al⁸ reported that individuals with the *IRS1* rs2943641 CC genotype were more successful with weight loss than those without this genotype when assigned to a low-fat and high-carbohydrate diet vs a low-carbohydrate and high-fat diet. Grau et al³² reported that individuals with the *FTO* rs9939609 TT genotype had greater decreases in the homeostatic assessment model of insulin resistance on low-fat vs low-carbohydrate diets; however, the diet-genotype interaction for weight loss was not statistically significant. Most prior studies examined single SNPs, with few replication attempts. The intent in the current study was to replicate the post hoc findings from the A TO Z (Atkins, Traditional, Ornish, Zone) Weight Loss Study.³

The finding of no significant difference in weight loss in genotype-matched vs mismatched groups in the current study highlights the importance of conducting large, appropriately powered trials such as DIETFITS for validating early exploratory analyses. Analyses of all the genomic data obtained are under way to evaluate whether other genetic signatures may demonstrate effect modification.

Several research groups previously reported observing a differential effect of low-fat vs low-carbohydrate diets on weight loss by baseline insulin status. In both a 6-month feeding study with 32 participants and an 18-month free-living study with 56 participants, effect modification between diet assignment (low-fat vs low-carbohydrate or low glycemic load) and INS-30 was reported.^{12,13} Using fasting insulin cutoffs in a 4-month feeding study involving 20 par-

ticipants, Cornier et al¹¹ observed a significant diet × fasting insulin interaction for weight loss. A post hoc analysis from the A TO Z Study revealed a significant diet × fasting insulin interaction on 12-month weight loss among a subset of 81 overweight and obese women.¹⁴

However, in a recent pilot study conducted in preparation for the DIETFITS study, a significant effect modification was not detected for INS-30 status.³⁵ In each case in which a significant interaction was reported, investigators proposed a mechanism involving insulin secretion status, insulin sensitivity, or insulin resistance interacting with glycemic load to differentially affect weight loss response with low-fat diets high in carbohydrates vs high-fat diets low in carbohydrates.^{12,36}

In these studies, the consistent direction of the finding was that a lower carbohydrate diet was superior for those individuals with higher insulin secretion or higher insulin resistance; the putative mechanism involves a lower demand or burden on insulin-mediated glucose disposal for those with impaired insulin metabolism while maintaining a lower carbohydrate and higher fat diet. Despite mechanistic plausibility, studies to date have involved relatively small sample sizes.

Effect modification claims observed in single randomized trials are often spurious and this result is even more frequent when small sample sizes and post hoc analyses are involved; validation of such claims is infrequent.³⁷⁻³⁹ The current study with a larger sample, a low-carbohydrate diet that was also a low glycemic load diet, and using INS-30 could not replicate findings from prior studies using smaller numbers of patients or those studies with a shorter duration. We consider the differences between the current findings and the studies cited to potentially involve diet quality beyond simply differentiating fat and carbohydrate intake. In this regard, refined grains are low in fat but considered of poor nutritional quality due to low-nutrient density relative to energy content. In contrast, vegetables are high in nutrient density, and relatively high in proportional carbohydrate content, but low in calories. Both diet groups in the current study were instructed to minimize or eliminate refined grains and added sugars and maximize intake of vegetables. We conclude that when equal emphasis is given to high dietary quality for both low-fat and low-carbohydrate eating plans, it is not helpful to preferentially direct an individual with high insulin secretion status who is seeking weight loss to follow a lower-carbohydrate eating plan instead of a lower-fat eating plan.

This study had several strengths. Study design strengths included the similarly intensive demands on both diet groups in making changes to baseline diets, similar focus on dietary quality, repeated major time points of data collection, and the extensive range of types of data collected. Strengths in study conduct included meeting and exceeding the sample size target of 600 participants, the nearly equal proportions of women and men enrolled, high and equivalent retention for both diet groups, and comparability of change between groups in potentially important outcomes related to weight loss, such as physical activity. In addition, the collective loss of approximately 3000 kg among study participants, and the wide individual variability of weight loss, provided the opportunity to meaningfully test for effect modification.

Limitations

The study also has several limitations. First, generalizability of the findings may be limited by the conduct of the study in a geographic area with individuals who have attained relatively high education levels, and have personal resources and high accessibility to high-quality food options. To address this, the study was broadly advertised and successfully enrolled participants with relatively good ethnic and racial diversity, and a range, albeit limited, of educational attainment.

Second, in regard to the possible role of insulin-glucose dynamics as an effect modifier in low-fat vs low-carbohydrate studies, there are many possible indices to consider other than INS-30,³⁶ a proxy measure of insulin secretion selected for reasons described elsewhere.^{12,13} But others have reported finding significant effect modification according to prestudy fasting insulin concentrations.^{11,14}

Third, there were 3 missing secondary anthropometric and metabolic variables (percentage of body fat, resting energy expenditure, and respiratory exchange ratio) for the first 78 participants enrolled in the study due to inadequate initial funding. This funding situation subsequently changed (described in eAppendix 1 in Supplement 2), which allowed the addition of these measurements for the remaining participants enrolled.

Fourth, the Stanford 7-day Physical Activity Recall tool (which was used to determine total energy expenditure) provides only a relatively crude assessment of total energy expenditure. Another method of measuring energy expenditure, such as the doubly labeled water method, would have provided greater accuracy; however, the overall cost and added

participant burden were determined to be beyond the scope of the study. In addition, self-reported diet assessment methods are all known to have limited accuracy; therefore, we chose to use the Nutrition Data System for Research, which is recognized as a top method.

Fifth, even though insulin sensitivity was well assessed in this study, assessment of genetic characteristics as effect modifiers of diet response need better and increased study in the future because there has been much progress in understanding the genetic architecture of metabolic phenotypes such as obesity since the current trial was designed. Other explanations for heterogeneity besides insulin dynamics and genetic characteristics also need to be assessed.

Sixth, by not randomizing or conducting stratification according to genotype or insulin secretion status, the level of causal inference to be drawn from the analyses of interactions was limited; however, this allowed us to test for 2 primary interaction associations in the same study.

Conclusions

In this 12-month weight loss diet study, there was no significant difference in weight change between a healthy low-fat diet vs a healthy low-carbohydrate diet, and neither genotype pattern nor baseline insulin secretion was associated with the dietary effects on weight loss. In the context of these 2 common weight loss diet approaches, neither of the 2 hypothesized predisposing factors was helpful in identifying which diet was better for whom.

ARTICLE INFORMATION

Accepted for Publication: January 17, 2018.

Author Contributions: Dr Gardner had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Gardner, Rigdon, Ioannidis, Desai, King.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Gardner, Trepanowski, Del Gobbo, Hauser, Rigdon, Desai.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Gardner, Del Gobbo, Hauser, Rigdon, Ioannidis, Desai.

Obtained funding: Gardner.

Administrative, technical, or material support: Gardner, Hauser, King.

Supervision: Gardner, Desai, King.

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Funding/Support: This study was supported by grant 1R01DK091831 from the National Institute of Diabetes and Digestive and Kidney Diseases, grant T32HL007034 from the Nutrition Science Initiative, grant 1K12GM088033 from the National Heart, Lung, and Blood Institute, and the Stanford Clinical and Translational Science Award.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the other funders.

Additional Contributions: This study would not have been possible without the work of the following individuals who were affiliated with Stanford University at the time of the study and who received compensation for their work: Jennifer Robinson, PhD, and Antonella Dewell, MS, RD (served as study coordinators), Rise Cherin, MS, RD, Susan Kirkpatrick, RD, CDE, Jae Berman, MS, RD, CSSD, Dalia Perelman, MS, RD, CDE, and Mandy Murphy Carroll, MPH, RD (health educators), Sarah Farzinkhou, MPH, Valerie Alaimo, BS, Margaret Shimer Lawton, MPH, and Diane Demis, BS (diet assessment team), Josephine Hau, MPH, RD, Erin Avery, MS, Alexandra Rossi, BS, Katherine Dotter, BS, RD, and Sarah Mummah, PhD (involved in recruitment, screening, blood sample management, innovation, and other tasks), Ariadna Garcia, MS, FeiFei Qin, MPH, and Vidhya Balasubramanian, MS (involved in statistical support), Alana Koehler, BA (administrative support), and Lucia Aronica, PhD, Jennifer Hartle, DrPH, MHS, CIH, Lisa Offringa, PhD, Kenji Nagao, PhD, Marilyn Oppezzo, PhD, MS, RD,

Benjamin Chrisinger, MUEP, PhD, and Michael Stanton, PhD (aided various phases of the study). We also acknowledge the 609 study participants without whom this investigation would not have been possible.

REFERENCES

- Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. *JAMA*. 2016;315(21):2284-2291.
- Zylke JW, Bauchner H. The unrelenting challenge of obesity. *JAMA*. 2016;315(21):2277-2278.
- Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. *JAMA*. 2007;297(9):969-977.
- Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *N Engl J Med*. 2009;360(9):859-873.
- Shai I, Schwarzfuchs D, Henkin Y, et al; Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. *N Engl J Med*. 2008;359(3):229-241.
- Johnston BC, Kanters S, Bandayrel K, et al. Comparison of weight loss among named diet

programs in overweight and obese adults: a meta-analysis. *JAMA*. 2014;312(9):923-933.

7. Field AE, Camargo CA Jr, Ogino S. The merits of subtyping obesity: one size does not fit all. *JAMA*. 2013;310(20):2147-2148.
8. Qi Q, Bray GA, Smith SR, Hu FB, Sacks FM, Qi L. Insulin receptor substrate 1 gene variation modifies insulin resistance response to weight-loss diets in a 2-year randomized trial: the Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial. *Circulation*. 2011;124(5):563-571.
9. Dopler Nelson M, Prabakar P, Kondragunta V, Kornman KS, Gardner CD. Genetic phenotypes predict weight loss success: the right diet does matter. Paper presented at: joint conference of the 50th Cardiovascular Disease Epidemiology and Prevention and Nutrition, Physical Activity, and Metabolism; March 2-3, 2010; San Francisco, CA.
10. Stanton MV, Robinson JL, Kirkpatrick SM, et al. DIETFITS study (Diet Intervention Examining The Factors Interacting With Treatment Success): study design and methods. *Contemp Clin Trials*. 2017;53:151-161.
11. Cornier MA, Donahoo WT, Pereira R, et al. Insulin sensitivity determines the effectiveness of dietary macronutrient composition on weight loss in obese women. *Obes Res*. 2005;13(4):703-709.
12. Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. *JAMA*. 2007;297(19):2092-2102.
13. Pittas AG, Das SK, Hajduk CL, et al. A low-glycemic load diet facilitates greater weight loss in overweight adults with high insulin secretion but not in overweight adults with low insulin secretion in the CALERIE Trial. *Diabetes Care*. 2005;28(12):2939-2941.
14. McClain AD, Otten JJ, Hekler EB, Gardner CD. Adherence to a low-fat vs low-carbohydrate diet differs by insulin resistance status. *Diabetes Obes Metab*. 2013;15(1):87-90.
15. Physical Activity Guidelines Advisory Committee, US Office of Disease Prevention and Health Promotion. 2008 physical activity guidelines for Americans. <https://health.gov/paguidelines/guidelines/>. Accessed November 21, 2017.
16. Bandura A. *Self-Efficacy: The Exercise of Control*. New York, NY: WH Freeman and Co; 1997.
17. Foreyt JP, Goodrick GK. Impact on behavior therapy on weight loss. *Am J Health Promot*. 1994;8(6):466-468.
18. King AC, Frey-Hewitt B, Dreon DM, Wood PD. Diet vs exercise in weight maintenance: the effects of minimal intervention strategies on long-term outcomes in men. *Arch Intern Med*. 1989;149(12):2741-2746.
19. Feskanich D, Sliaff BH, Chong K, Buzzard IM. Computerized collection and analysis of dietary intake information. *Comput Methods Programs Biomed*. 1989;30(1):47-57.
20. Sallis JF, Haskell WL, Wood PD, et al. Physical activity assessment methodology in the Five-City Project. *Am J Epidemiol*. 1985;121(1):91-106.
21. Chiu KC, Martinez DS, Yoon C, Chuang LM. Relative contribution of insulin sensitivity and beta-cell function to plasma glucose and insulin concentrations during the oral glucose tolerance test. *Metabolism*. 2002;51(1):115-120.
22. Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. *Diabet Med*. 1994;11(3):286-292.
23. Hron BM, Ebbeling CB, Feldman HA, Ludwig DS. Relationship of insulin dynamics to body composition and resting energy expenditure following weight loss. *Obesity (Silver Spring)*. 2015;23(11):2216-2222.
24. Chaput JP, Tremblay A, Rimm EB, Bouchard C, Ludwig DS. A novel interaction between dietary composition and insulin secretion: effects on weight gain in the Quebec Family Study. *Am J Clin Nutr*. 2008;87(2):303-309.
25. Ludwig DS, Majzoub JA, Al-Zahrani A, Dallal GE, Blanco I, Roberts SB. High glycemic index foods, overeating, and obesity. *Pediatrics*. 1999;103(3):E26.
26. Goni L, Cuervo M, Milagro FI, Martínez JA. Future perspectives of personalized weight loss interventions based on nutrigenetic, epigenetic, and metagenomic data. *J Nutr*. 2016;146(4):905S-912S.
27. Diggle P. *Analysis of Longitudinal Data*. Oxford, England: Oxford University Press; 2002.
28. Batterham MJ, Tapsell LC, Charlton KE. Analyzing weight loss intervention studies with missing data: which methods should be used? *Nutrition*. 2013;29(7-8):1024-1029.
29. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest: tests in linear mixed effects models. R package version 2.0-33. <https://cran.r-project.org/>. Accessed January 10, 2018.
30. Bates D, Mächler M, Bolker BM, Walker SC. Fitting linear mixed-effects models using lme4. *J Stat Softw*. 2015;67(1):1-48.
31. Bray MS, Loos RJ, McCaffery JM, et al; Conference Working Group. NIH working group report—using genomic information to guide weight management: from universal to precision treatment. *Obesity (Silver Spring)*. 2016;24(1):14-22.
32. Grau K, Cauchi S, Holst C, et al. TCF7L2 rs7903146-macronutrient interaction in obese individuals' responses to a 10-wk randomized hypoenergetic diet. *Am J Clin Nutr*. 2010;91(2):472-479.
33. Heianza Y, Ma W, Huang T, et al. Macronutrient intake-associated FGF21 genotype modifies effects of weight-loss diets on 2-year changes of central adiposity and body composition: the POUNDS Lost trial. *Diabetes Care*. 2016;39(11):1909-1914.
34. Qi Q, Bray GA, Hu FB, Sacks FM, Qi L. Weight-loss diets modify glucose-dependent insulinotropic polypeptide receptor rs2287019 genotype effects on changes in body weight, fasting glucose, and insulin resistance: the Preventing Overweight Using Novel Dietary Strategies trial. *Am J Clin Nutr*. 2012;95(2):506-513.
35. Gardner CD, Offringa LC, Hartle JC, Kapphahn K, Cherin R. Weight loss on low-fat vs low-carbohydrate diets by insulin resistance status among overweight adults and adults with obesity: a randomized pilot trial. *Obesity (Silver Spring)*. 2016;24(1):79-86.
36. Pittas AG, Roberts SB. Dietary composition and weight loss: can we individualize dietary prescriptions according to insulin sensitivity or secretion status? *Nutr Rev*. 2006;64(10 pt 1):435-448.
37. Sun X, Ioannidis JP, Agoristas T, Alba AC, Guyatt G. How to use a subgroup analysis: Users' Guide to the Medical Literature. *JAMA*. 2014;311(4):405-411.
38. Wallach JD, Sullivan PG, Trepanowski JF, Steyerberg EW, Ioannidis JPA. Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses. *BMJ*. 2016;355:i5826.
39. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. *J Clin Epidemiol*. 2004;57(3):229-236.